CVAC and FANS reflect different surgical philosophies—dusting vs fragmentation—with distinct ergonomic trade-offs and shared intrarenal pressure risks that urologists must actively monitor, according ...

FDA cleared Titan Prime, a next-generation IPP, emphasizing improved flaccid flexibility intended to enhance comfort and concealability for erectile dysfunction patients. Approval of generic Ga-68 ...

In this episode, Anup A. Vora, MD, discusses patient selection for focal therapy in localized prostate cancer, the role of precision medicine, and how advanced practice providers are helping deliver ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.

"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.

Mechanistically, Anktiva increases circulating lymphocyte counts by proliferating NK and CD8+ T cells and supporting memory formation, an immune-support role likened to erythroid and neutrophil growth ...

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...

Researchers at the Mayo Clinic report that they have developed a legitimate penile traction therapy device for men with Peyronie’s disease that may work when used for just 30 to 90 minutes daily.

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...